Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma

    Access Status
    Fulltext not available
    Authors
    Saei, A.
    Eichhorn, Pieter
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Saei, A. and Eichhorn, P. 2018. Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma. Molecular and Cellular Oncology. 5 (5).
    Source Title
    Molecular and Cellular Oncology
    DOI
    10.1080/23723556.2018.1497862
    ISSN
    2372-3556
    School
    School of Pharmacy and Biomedical Sciences
    URI
    http://hdl.handle.net/20.500.11937/72815
    Collection
    • Curtin Research Publications
    Abstract

    © 2018, © 2018 The Author(s). Published by Taylor & Francis. Response to targeted therapies is limited by the activation or inhibition of feedback loops. Here we report the ubiquitin specific peptidase 28/F-box WD repeat-containing protein 7 (USP28/FBW7) complex functions as a negative regulator of mitogen-activated protein kinase (MAPK) pathway by targeting v-raf murine sarcoma viral oncogene homolog B (BRAF) for degradation, a process which is lost in a large proportion of BRAF mutant melanoma patients, resulting in resistance to BRAF inhibitor therapies.

    Related items

    Showing items related by title, author, creator and subject.

    • Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation
      Bentel, J.; Thomas, M.; Rodgers, J.; Arooj, Mahreen; Gray, E.; Allcock, R.; Fermoyle, S.; Mancera, R.; Cannell, P.; Parry, J. (2017)
      BRAF mutation testing to determine eligibility for treatment with vemurafenib was performed on archival skin lesions of a 54-year-old patient diagnosed with Erdheim-Chester disease (ECD) in 1999. Sanger sequencing of DNA ...
    • Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
      Saei, A.; Palafox, M.; Benoukraf, T.; Kumari, N.; Jaynes, P.; Iyengar, P.; Muñoz Couselo, E.; Nuciforo, P.; Cortés, J.; Nötzel, C.; Kumarakulasinghe, N.; Richard, J.; Isa, Z.; Pang, B.; Guzman, M.; Siqin, Z.; Yang, H.; Tam, W.; Serra, V.; Eichhorn, Pieter (2018)
      © 2018 Saei et al. RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially ...
    • Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population
      Cenin, Dayna; Naber, S.; Lansdorp-Vogelaar, Iris; Jenkins, M.; Buchanan, D.; Preen, D.; Ee, H.; O'Leary, Peter (2018)
      © 2018 The Authors Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: Individuals with Lynch syndrome ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.